Clinical trials: ILD
Idiopathic Pulmonary Fibrosis
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FG-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor…
- Trial name
- NCT00074698
- Testing
- FG-3019
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Kyntra Bio
Regional Anesthesia, Diaphragm Issues
Ultrasound Assessment of Diaphragmatic Dysfunction in Regional Anesthesia
Awake thoracic surgery is a feasible and safe alternative to general anesthesia for pulmonary biopsy in interstitial lung disease patients, but there is still no evidence as to its superiority in terms of outcome.
- Conditions
- Regional Anesthesia, Diaphragm Issues, Thoracic Surgery, Ultrasounds
- Trial name
- NCT04700943
- Testing
- Regional awake anesthesia
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- University of Turin, Italy
Interstitial Lung Disease
Value of Chest Ultrasonography in ILD Screening
The main aim of this study is to detect the value of transthoracic ultrasonography in the diagnosis and assessment of ILDs in correlation to chest X- ray, blood gases, pulmonary function test and echocardiography and to compare…
- Trial name
- NCT06260930
- Volunteers
- 80 people
- Sponsor
- Aswan University
Chronic Obstructive Pulmonary Disease, Asthma
Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects
The first-in-man study are designed as below to assess safety, tolerability, and preliminary pharmacokinetics of ZL-2102. Double-blind randomized, placebo-controlled ascending single oral doses (Part 1, ZL-2102-SAD); Open-label…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02397005
- Testing
- ZL-2102
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Zai Lab Pty. Ltd.
Lung Cancer, Sarcoidosis
Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy
After randomization, the subjects undergo flexible bronchoscopy either with fractionated propofol administration or with propofol-TCI.
- Conditions
- Lung Cancer, Sarcoidosis, Interstitial Pneumonia
- Trial name
- NCT02246023
- Testing
- Flexible bronchoscopy in moderate sedation, Oxygen saturation, Blood pressure
- Where
- Switzerland
- Volunteers
- 78 people
- Sponsor
- Daniel Franzen
Idiopathic Pulmonary Fibrosis
NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib
To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD) patients…
- Trial name
- NCT04614441
- Testing
- OFEV®
- Where
- 26 sites in Taiwan
- Volunteers
- 214 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Sleep Disorders in Idiopathic Pulmonary Fibrosis
This diagnostic observational study was conducted to (1) investigate the prevalence of sleep-related breathing disorders and other sleep disorders in idiopathic pulmonary fibrosis in comparison to COPD, (2) identify…
- Trial name
- NCT05113654
- Testing
- Sleep study
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Wissenschaftliches Institut Bethanien e.V
Idiopathic Pulmonary Fibrosis
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- NCT06967805
- Testing
- MTX-463
- Where
- 59 sites in United States, Argentina and 9 more
- Volunteers
- 168 people
- Sponsor
- Mediar Therapeutics
Idiopathic Pulmonary Fibrosis, Lung; Disease, Interstitial, With Fibrosis
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
This is a phase 1, randomized, First in Human (FIH), double-blinded, placebo-controlled study to assess the safety, tolerability, and PK of RSN0402 in healthy volunteers.
- Trial name
- NCT06482190
- Testing
- RSN0402 Part 1, RSN0402 Part 2
- Where
- 3 sites in Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shenzhen Resproly Biopharmaceutical Co., Ltd
Antisynthetase Syndrome
Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease
Antisynthetase syndrome (AS) is a rare overlapping myositis characterized by cellular and humoral autoimmune responses directed against aminoacyl-tRNA synthetases.
- Trial name
- CYTILDASS (NCT05984394)
- Testing
- BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Central Hospital, Nancy, France
Idiopathic Pulmonary Fibrosis
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis.
- Trial name
- GAP (NCT00373841)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Pittsburgh
Interstitial Lung Disease, Systemic Sclerosis
The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis
Scarring of the lungs is common in patients with scleroderma and is one of the main causes of death. Patients with scleroderma very frequently have problems with their gullet (esophagus), the food pipe that leads into the…
- Conditions
- Interstitial Lung Disease, Systemic Sclerosis, Gastroesophageal Reflux
- Trial name
- NCT02136394
- Testing
- Gastro-esophageal reflux
- Where
- 2 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Myelofibrosis, Gaucher Disease
Clinical and Pathophysiological Investigations Into Erdheim Chester Disease
Background: Erdheim Chester Disease (ECD) is a very rare disease in which abnormal white blood cells start growing and affect the bones, kidneys, skin, and brain.
- Conditions
- Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS)
- Trial name
- NCT01417520
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Idiopathic Interstitial Pneumonias
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
We hypothesize that a peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose…
- Trial name
- NCT01151527
- Where
- 2 sites in United States
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Duke University
Idiopathic Pulmonary Fibrosis
Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy
Post-marketing surveillance of Pirfenidone
- Trial name
- NCT03761082
- Testing
- NA(observation study)
- Volunteers
- 258 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
This study is meant to compare the amount of oxygen required for hypoxemia relief between current standard of care (oxygen only) and oxygen with the addition of high flow air for Chronic Obstructive Pulmonary Disease (COPD)…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Pulmonary Fibrosis, Hypoxemia
- Trial name
- NCT04170062
- Testing
- Nasal Delivery of High-Flow Air and Oxygen Therapy, Nasal Delivery of Oxygen Therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Johns Hopkins University
Interstitial Pneumonia
The Clinical Course of Interstitial Pneumonia With Autoimmune Features
Interstitial pneumonia with autoimmune features (IPAF) is a chronic interstitial lung disease (ILD) with some laboratoristic and/or clinical features of autoimmune disease, but without meeting criteria of connective tissue…
- Trial name
- NCT03950583
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Fibrosing Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis
Yoga in Patients With Fibrosing Interstitial Lung Diseases
Fibrosing interstitial lung diseases are characterized by loss of lung function, which leads to a decrease in quality of life and physical capacity.
- Trial name
- NCT03979703
- Testing
- 12 week yoga class
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Heidelberg University
Pulmonary Fibrosis, Interstitial Lung Disease
The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19
Up to a third of patients who recovered from SARS coronavirus (SARS-CoV) had a 20% decline in lung function with a long term reduction in exercise capacity and SF-36 health status a year after infection.
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Covid19
- Trial name
- MONACO (NCT04805086)
- Testing
- MON002
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Dermatopolymyositis, Interstitial Lung Disease
Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis
Interstitial lung disease (ILD) is a common complication of dermatomyositis (DM) with prevalence up to 65%, and is considered to be one of the determining factors of prognosis.
- Trial name
- NCT02821689
- Testing
- Pirfenidone
- Where
- China
- Volunteers
- 57 people
- Sponsor
- RenJi Hospital